Introduction
Neutropenia is a commonly seen serious adverse effect of cancer treatment (1, 2, 3) . The incidence of neutropenia decreases by 50 % with the use of granulocyte colony-stimulating factor (G-CSF) (4, 5) . The most commonly used G-CSF preparations in Turkey and worldwide are fi lgrastim and lenograstim (6) . Patients may experience adverse effects including headache, bone pain, myalgia and arthralgia related to G-CSF which are usually managed using pharmacological agents (3, (7) (8) (9) (10) (11) .
Pain management varies, and is complex because of individual differences and circadian pain behavior (12, 13) . It has been suggested that pain varies with individuals and different diseases, and because the circadian rhythm infl uences the pharmacodynamic and pharmacokinetic properties of the drugs, pain management should be conservative and individualized (12) . In a study on circadian changes during a 24-h period induced by CFU-GM in bone marrow, the production of myeloid progenitor cells has been reported to start to increase at 04.00, peak at 12.00 p.m. and start to decrease at 16.00 p.m. (14) . During the 24-h circadian rhythm of bone marrow, the percentage of bone marrow cells at the DNA synthesis phase is 188% higher in the midday compared to midnight with a similar circadian change seen in granulocyte/macrophages during the DNA synthesis phase (15) .
Although there are several previous studies investigating the relationship between the circadian rhythm and proliferation of bone marrow cells or pain (12, 14, 15) , to the best of our knowledge, no studies have investgated the circadian rhythm in pain induced by G-CSF treatment used to induce neutrophile proliferation. This semi-experimental study was planned in order to investigate the infl uence of administration time of G-CSF on myalgia and arthralgia induced by the drug used to prevent neutropenia in cancer patients.
Material and methods

Study design
This semi-experimental, self-controlled study was conducted in order to investigate the effect of administration time of fi lgrastim on myalgia and arthralgia induced by fi lgrastim used to prevent neutropenia in cancer patients.
Study setting and population
The study was carried out at the chemotherapy unit of hospital at Eskisehir between November 31, 2014 and July 31, 2015. Study population consisted of patients who had received G-CSF treatment the day after chemotherapy. The study sample con-sisted of patients meeting inclusion criteria and agreeing to participate in the study. Study sample excluded the patients who reported to have used analgesic medication during fi lgrastim application.
Inclusion criteria: -Being literate, -Having no mental or communication problems, -Being over 18 years and under 74 years of age, -Having ability to self-administer subcutaneous 30 MIU G-CSF (fi lgrastim) -Agreeing to participate in the study.
The repeated measures of Anova statistical power analysis was conducted in order to determine the adequacy of sample size. In the statistical power analysis based on Quantitative Pain Assessment Scale value, the number of units for each group was determined as 7 for the effect power of 0.99 % with a α value of 0.05, and β value of 0.0033.
Outcome measures
Data were collected through observation, face-to-face-interview and measurement methods, and by using Patient Identifi cation Form and Quantitative Pain Assessment Scale.
Patient Identifi cation Form: The form prepared by the researchers consists of 16 items regarding sociodemographic features and disease-and treatment-related factors (16, 17) .
Quantitative Pain Assessment Scale (QPAS): This scale assessing the pain severity aims to quantify the pain of patient. The scores of the scale range from 0 to 10 with 0 indicating no pain and 10 indicating intolerable pain severity (18) .
Data collection procedure
The patients who met the inclusion criteria were systematically assigned into two groups (A and B) by using a simple randomization method. First and second stages of the study were carried out in both groups of patients.
First stage: The fi lgrastim treatment was planned to be selfadministered the day after chemotherapy by the patient according to the decision of physician who instructed the administration to be carried out at 10: 00 in group A and at 14: 00 in group B. Patients were also asked to assess their pain level by using Quantitative Pain Assessment Scale every four hours after the drug administration for a total of 4 times (Tab. 1).
Second stage: In this stage, patients in group A and B were asked to self-administer fi lgrastim at 14: 00 p.m. and 10: 00, respectively. Again, patients were instructed to assess their pain level by using Quantitative Pain Assessment Scale every four hours after the drug administration for a total of 4 times (Tab. 1). Because the drugs in our country are most commonly administered at 10: 00 and 14: 00, fi lgrastim was instructed to be administered at these particular points of time.
Data analysis
All data were analyzed by using SPSS 21.0 package program (19) . Continuous quantitative data are given as n, mean and standard error while qualitative data are given as n, median, 25th and 75 th percentiles. Kruskal-Wallis and Mann-Whitney U tests were used for data series consisting of independent measurements or scoring and Wilcoxon Signed Ranks test was used for dependent variables. The signifi cance level was set at p < 0.05.
Ethical considerations
This study was approved by Ethical Committee of Hospital (approval date/number: November 14, 2014/2014-210). After giving written and verbal information, all study subjects gave written consent. They were informed on the fact that if they wanted to discontinue participation, they could leave the study without stating their reason.
Results
Socio-demographic and clinical characteristics of the sample
The total of 48 patients with cancer were included in the analysis (22 men and 26 women). During the study period, a total of 15 patients were excluded from the study because 11 patients were reported to have been using analgesic medication regularly, and 4 patients did not complete the study. The mean age of the study population was 56.52 ± 12.08 years (57.66 ± 11.76 years in group A and 55.38 ± 12.54 years in group B). Of the patients, 54.2 % were female, 45.8 % were male, 41.7 % were secondary school graduates and majority (89.6 %) were married. Of the patients included in the study, 33.3 %, 25 %, 12.5 %, and 8.4 % had breast carcinoma, gastrointestinal cancers, lung cancer, hematological cancers, soft tissue cancer, respectively and and 41.7 % were at the second stage of the disease. Chemotherapy-induced neutropenia was seen in 83.3 %, while 81.3 % of patients had fi lgrastim administered previously (mean 2.47 ± 1.68) (Tab. 2). 
Assessment of patients according to inclusion criteria
Effectiveness of administration time of fi lgrastim in pain
Previous fi lgrastim was reported to cause diffuse bodily pain in 79.1 %. Of these patients, 50.4 % used analgesic medication, 27.1 % used analgesics, relaxation techniques, massage, and resting for pain management while 18.8 % used no intervention in prior usage of fi lgrastim (Tab. 2). In group A, the pain score in the fi rst stage (fi lgrastim administered at 10: 00) was signifi cantly higher compared to fi lgrastim administered at 14: 00 in the second stage (0th hour: p = 0.020; 4th hour: p = 0.01; 8th hour: p < 0.001; 12th hour: p < 0.012) (Tab. 3). On the other hand, in group B patients, the pain score in the fi rst stage (fi lgrastim administered at 14: 00 p.m.) was signifi cantly lower than that in the second stage (fi l- grastim administered at 10: 00; 0th hour: p = 0.564; 4th hour: p = 0.016; 8th hour: p = 0.027; 12th hour: p = 0.012) (Tab. 3).
Socio-demographic characteristics of effectiveness of administration time of fi lgrastim relative to pain
There was no signifi cant relation between pain severity scored after different fi lgrastim administration times and gender, marital status, educational status and previous fi lgrastim administrations (p > 0.059) (Tab. 4), while mean pain scores were found to be signifi cantly lower in higher educated subjects compared to solely literate subjects (p = 0.034).
Discussion
Pain is a well-known complication of G-CSF administration. In the present study, fi lgrastim was reported to cause diffuse bodily pain in 91.7 %, while previous use of fi lgrastim was reported to cause diffuse bodily pain in 79.1 %. The mechanisms of bone pain secondary to G-CSF are not fully known but recent studies have been reported to range from 19 % to 59 %. Bone pain develops in patients treated with pegfi lgrastim and fi lgrastim (2, 7, 8, 11, 20, 21) . On account of bone pain is a well-known complication of G-CSF, pain is treated with drugs (8, 9, 11, 20, 21, 22) . Accordingly, in the study by Ogata et al (2005) , G-CSF administration resulted in bone pain in 10 % of patients in whom the pain management included nonsteroidal antiinfl ammatory drugs (NSAIDs) and hydroxyzine. In the study by Kirshner et al (2012) , bone pain associated G-CSF should be treated with naproxen while pain relief in patients managed with hydroxyzine but not in those managed with NSAIDs in the study of Ogata et al (2005) (11, 21) . According to Carr (2012) , mild bone pain induced by G-CSF should be treated with paracetamol but the number of G-CSF administration days and/or G-CSF dose should be changed in the case of intoler- able severe pain (9) . Some works also reported that patients were treated with loratadine (8, 20) . It has been emphasized that paying attention to circadian rhythm with determination of the dose and administration time of the drug is essential for the best pharmacokinetic results of the drugs (23, 24) . It has been also suggested to the drug administrating health professionals to consider the factors that are associated with the pharmacokinetic features of the drug, such as the activity and resting periods of the patient, posture, meal times and meal contents, and galenic formulations particularly when using the drugs with a narrow therapeutic window (25) . However, literature search revealed no studies assessing the relationship between G-CSF administration time and pain level. Authors of this study planned the present a study with the hypothesis that G-CSF administration time affects the level of G-CSF-associated pain and found that the pain was statistically signifi cantly lower when G-CSF was administered at 14: 00 compared to administration at 10: 00 In the study by Mendez-Ferrer et al (2008), circulation of hematopoietic stem cells has been reported to peak 5 hours after sunrise, decrease 5 hours after sunset and circulate during the day (26) . The authors have also suggested that activation of the nervous system also changes in relation to these circadian rhythms. Saba et al (2013) have also reported similar fi ndings (27) . In studies examining the effects of circadian ryhtm and exercise on homeostasis, exercise was found to infl uence platelet synthesis (28, 29) with increased platelet synthesis during daylight (29) . MoraRodriguez and Coyle (2000) have reported signifi cantly increased plasma norepinephrine level with exercise (30) with another study reporting that G-CSF and adrenergic signal collaborate to trigger the output of hematopoietic stem cells to the peripheral area (31) . In our study, it has been considered that the reason of lower pain level with G-CSF administered at 14: 00 p.m. may be associated with the effect of circadian ryhtm and exercise via increasing the concentration of hematopoietic stem cells in daytime (26, 28, 29, 31) and that with G-CSF administered at 10: 00, pain level might increase 4 and 8 hours after injection because of overstimulation of bone marrow. Accordingly, the decreased hematopopietic stem cell circulation after sunset (26) may be associated with lower pain level assessed 4 and 8 hours after G-CSF administration at 14: 00 p.m.
Conclusion
It was determined in the present study that in order to minimize the pain, it will be more benefi cial to administer G-CSF at 14: 00. This should be of importance in the nursing practice aimed at pain reduction and sustenance of the quality of life of patients, thus enabling uninterrupted treatment.
